Business Wire

OCTAPHARMA

17.9.2020 13:53:05 CEST | Business Wire | Press release

Share
Patient recruitment starts for the international PRO-SID study evaluating Panzyga® for primary prophylaxis in patients with chronic lymphocytic leukaemia and secondary immunodeficiency

Octapharma is pleased to announce that the first site for the international PRO-SID (Primary Infection Prophylaxis with Panzyga® in Secondary Immunodeficiency in Chronic Lymphocytic Leukaemia) study was initiated in Milan, Italy, and patient recruitment is underway. Additional sites across Europe (Italy, Poland, Denmark, Hungary, Germany and Russia) and the USA are expected to begin recruitment soon. PRO-SID is the first randomised, placebo-controlled study to systematically evaluate the efficacy and safety of IVIG for primary prophylaxis for infection control in patients with chronic lymphocytic leukaemia (CLL).

Secondary immunodeficiency (SID) is a common complication in patients with haematological malignancies such as CLL. Up to 85% of CLL patients develop hypogammaglobulinemia during the course of the disease, either due to the underlying disease or as a side effect of their treatment.1 For example, in one study, 39% of CLL patients developed hypogammaglobulinaemia after treatment with a B-cell depleting therapy.2 Patients with hypogammaglobulinaemia are more likely to develop infections, which are not only a major cause of morbidity but also account for up to 60% of deaths in patients with CLL.3 The use of intravenous immunoglobulins (IVIG) is well established as secondary prophylaxis to reduce the rate of infections in patients with haematological malignancies. However, there are insufficient data from well-designed, randomised, controlled studies to recommend IVIG as primary prophylaxis, before occurrence of the first major infection.4 For more information on SID and haematological malignancies, please visit https://www.secondaryimmunodeficiency.com/ .

The double-blind, randomised, placebo-controlled, prospective, multicentre phase III PRO-SID study (NCT04502030) was designed to assess the efficacy and safety of Panzyga® , a human immunoglobulin for intravenous administration, as primary prophylaxis in patients with CLL and SID. The study plans to recruit at least 240 adult patients with CLL and hypogammaglobulinaemia (IgG levels < 5 g/L) who are receiving antineoplastic treatment. The primary outcome is the occurrence of at least one major infection over 52 weeks in patients receiving Panzyga® compared with placebo. Both treatment groups will also receive standard of care infection prophylaxis. Secondary outcomes include the overall infection rate and the frequency and duration of prophylaxis with anti-infectives.

Wei Ding, M.B.B.S, PhD, Mayo Foundation for Medical Education and Research, member of the PRO-SID study steering committee, commented that: “Despite improved therapy options in CLL patients, infections are still one of the major causes of morbidity and mortality. Primary prophylaxis with IVIG before severe infections occur has the potential to reduce infection rates and the burden on patients and the healthcare system. There is a need for robust data on the efficacy and safety of this approach, and insights from the PRO-SID study may prove highly valuable for informing treatment decisions

Dr. Olaf Walter, Board Member at Octapharma, added: “There remains a significant need to reduce the burden of the disease in managing patients with haematological malignancies and secondary immunodeficiency. Initiation of the PRO-SID study represents a key milestone in Octapharma’s efforts to improve the care of patients with CLL.”

About the PRO-SID study
The PRO-SID study (NCT04502030) is a prospective, double-blind, randomised, multi-centre, placebo-controlled, interventional, phase III study investigating the efficacy and safety of Panzyga® in patients with chronic lymphocytic leukaemia (CLL) and hypogammaglobulinaemia (IgG < 5 g/L) who are receiving antineoplastic treatment. The study will be conducted at multiple sites across Europe (Italy, Poland, Denmark, Hungary, Germany and Russia) and the USA and plans to recruit at least 240 patients.

About Panzyga®
Panzyga® is a 10% human normal immunoglobulin solution ready for intravenous administration. Panzyga® is approved for use in treatment of primary immunodeficiency and idiopathic thrombocytopenic purpura in the USA, Europe and Canada. It is also approved for secondary immunodeficiencies and Guillain Barré syndrome in Europe and Canada and for CIDP in Europe.

About Octapharma
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.

Octapharma employs more than 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Haematology, Immunotherapy, and Critical Care.

Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, with a combined capacity of approximately 8 million litres of plasma per annum.

In addition, Octapharma operates more than 140 plasma donation centres across Europe and the USA.

References

1. Sanchez-Ramon S, et al. Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy. Front Immunol 2016; 7:317.

2. Casulo C, et al. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013; 13:106–111.

3. Tadmor T, et al. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. Exp Rev Hematol 2018; 11:57–70.

4. Agostini C, et al. Prophylactic immunoglobulin therapy in secondary immune deficiency –an expert opinion. Expert Rev Clin Immunol 2016; 12:921–926.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press release

Canada becomes the 25th Allied nation to back the NATO Innovation Fund, gaining access to €1.1 billion in mission-aligned capital and a co-investor network spanning the Alliance Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the amb

Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press release

Independent evaluation of Persona's Android SDK confirms defenses against deepfakes and other injected media at the top level of the first standard Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result

Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release

Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement

Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release

With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil

NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release

The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye